MX2018007361A - Moléculas pequeñas para inhibir la actividad de quimiocinas, la actividad de una cinasa y/o el crecimiento de células cancerosas. - Google Patents
Moléculas pequeñas para inhibir la actividad de quimiocinas, la actividad de una cinasa y/o el crecimiento de células cancerosas.Info
- Publication number
- MX2018007361A MX2018007361A MX2018007361A MX2018007361A MX2018007361A MX 2018007361 A MX2018007361 A MX 2018007361A MX 2018007361 A MX2018007361 A MX 2018007361A MX 2018007361 A MX2018007361 A MX 2018007361A MX 2018007361 A MX2018007361 A MX 2018007361A
- Authority
- MX
- Mexico
- Prior art keywords
- activity
- kinase
- chemiokines
- inhibit
- growth
- Prior art date
Links
- 230000000694 effects Effects 0.000 title abstract 3
- 108091000080 Phosphotransferase Proteins 0.000 title abstract 2
- 102000020233 phosphotransferase Human genes 0.000 title abstract 2
- 230000005907 cancer growth Effects 0.000 title 1
- 150000003384 small molecules Chemical class 0.000 title 1
- 102000019034 Chemokines Human genes 0.000 abstract 2
- 108010012236 Chemokines Proteins 0.000 abstract 2
- 230000004071 biological effect Effects 0.000 abstract 2
- 230000012292 cell migration Effects 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 208000027866 inflammatory disease Diseases 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 102000001253 Protein Kinase Human genes 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000004611 cancer cell death Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037765 diseases and disorders Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000006698 induction Effects 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 108060006633 protein kinase Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/24—Oxygen atoms attached in position 8
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/24—Oxygen atoms attached in position 8
- C07D215/26—Alcohols; Ethers thereof
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Ophthalmology & Optometry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Quinoline Compounds (AREA)
- Steroid Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
En el presente documento se proporcionan compuestos capaces de o que se pueden usar en la inducción de muerte de células cancerosas y/o la modulación de una actividad biológica de una quimiocina, por ejemplo, migración celular y/o el tratamiento de enfermedades y trastornos asociados a una actividad biológica de una quimiocina y/o migración celular y/o la inhibición de una cinasa y/o en el tratamiento de una enfermedad o un trastorno asociados a una actividad de una cinasa, tal como cáncer y enfermedades y trastornos inflamatorios. Los compuestos se representan de forma colectiva por las fórmulas Ia o Ib:(ver formulas) Fórmula Ia Fórmula Ib en las que A, B D, E, G y R1-R5 R5 son como se ha definido en la memoria descriptiva.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562268586P | 2015-12-17 | 2015-12-17 | |
| PCT/IL2016/051347 WO2017103932A1 (en) | 2015-12-17 | 2016-12-15 | Small molecules for inhibiting chemokine activity, a kinase activity and/or cancer cells growth |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2018007361A true MX2018007361A (es) | 2019-05-16 |
| MX382300B MX382300B (es) | 2025-03-13 |
Family
ID=59056164
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018007361A MX382300B (es) | 2015-12-17 | 2016-12-15 | Moléculas pequeñas para inhibir la actividad de quimiocinas y/o el crecimiento de células cancerosas. |
| MX2020011500A MX2020011500A (es) | 2015-12-17 | 2016-12-15 | Moléculas pequeñas para inhibir la actividad de quimiocinas, la actividad de una cinasa y/o el crecimiento de células cancerosas. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020011500A MX2020011500A (es) | 2015-12-17 | 2016-12-15 | Moléculas pequeñas para inhibir la actividad de quimiocinas, la actividad de una cinasa y/o el crecimiento de células cancerosas. |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US11129824B2 (es) |
| EP (2) | EP3390364B1 (es) |
| JP (1) | JP6941611B2 (es) |
| KR (1) | KR102828755B1 (es) |
| CN (1) | CN108699000B (es) |
| AU (2) | AU2016371466B2 (es) |
| CA (1) | CA3008107C (es) |
| DK (1) | DK3390364T3 (es) |
| ES (2) | ES2818531T3 (es) |
| IL (1) | IL260081B (es) |
| MX (2) | MX382300B (es) |
| WO (1) | WO2017103932A1 (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017103931A1 (en) | 2015-12-17 | 2017-06-22 | Biokine Therapeutics Ltd. | Small molecules against cancer |
| CA3008107C (en) | 2015-12-17 | 2023-06-27 | Biokine Therapeutics Ltd. | 8-phenoxy-quinoline derivatives for inhibiting chemokine activity and/or cancer cells growth |
| EP3759074B1 (en) * | 2019-05-15 | 2025-01-01 | AlonBio Ltd. | Small molecules for treating cancer, inhibiting chemokine activity and/or inducing cell death |
| JP2020193249A (ja) * | 2019-05-27 | 2020-12-03 | 信越化学工業株式会社 | 量子ドット、量子ドット組成物、波長変換材料、波長変換フィルム、バックライトユニット及び画像表示装置 |
| US20250368629A1 (en) * | 2022-06-13 | 2025-12-04 | Mayo Foundation For Medical Education And Research | Flavonoid compounds and methods and materials for using flavonoid compounds to treat fibrotic conditions |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5116964A (en) | 1989-02-23 | 1992-05-26 | Genentech, Inc. | Hybrid immunoglobulins |
| JPH06502845A (ja) | 1990-09-07 | 1994-03-31 | シェリング・コーポレーション | 抗ウイルス化合物および抗高血圧化合物 |
| JPH04178647A (ja) | 1990-11-14 | 1992-06-25 | Konica Corp | 有機着色物質の光褪色防止方法及びカラー写真材料 |
| US5710158A (en) | 1991-05-10 | 1998-01-20 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
| EP0584222B1 (en) | 1991-05-10 | 1997-10-08 | Rhone-Poulenc Rorer International (Holdings) Inc. | Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit egf and/or pdgf receptor tyrosine kinase |
| FR2682107B1 (fr) * | 1991-10-03 | 1995-04-21 | Orstom Inst Fs Rech Scient | Quinoleines 2-substituees pour le traitement des leishmanioses. |
| US6177401B1 (en) | 1992-11-13 | 2001-01-23 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften | Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis |
| US5998401A (en) | 1995-02-28 | 1999-12-07 | Eli Lilly And Company | Naphthyl compounds, intermediates, compositions, and methods |
| JP4471404B2 (ja) | 1996-02-13 | 2010-06-02 | アストラゼネカ ユーケイ リミテッド | Ｖｅｇｆインヒビターとしてのキナゾリン誘導体 |
| DE19638486A1 (de) | 1996-09-20 | 1998-03-26 | Basf Ag | Hetaroylderivate |
| US6002008A (en) | 1997-04-03 | 1999-12-14 | American Cyanamid Company | Substituted 3-cyano quinolines |
| KR20010052450A (ko) | 1998-05-28 | 2001-06-25 | 파커 휴우즈 인스티튜트 | 뇌종양 치료를 위한 퀴나졸린 |
| FR2781218B1 (fr) | 1998-07-15 | 2001-09-07 | Lafon Labor | Compositions pharmaceutiques comprenant des 2-quinolones |
| US6313129B1 (en) | 1998-08-21 | 2001-11-06 | Hughes Institute | Therapeutic compounds |
| US6660843B1 (en) | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
| US6258820B1 (en) | 1999-03-19 | 2001-07-10 | Parker Hughes Institute | Synthesis and anti-tumor activity of 6,7-dialkoxy-4-phenylamino-quinazolines |
| AU7031500A (en) | 1999-09-23 | 2001-04-24 | Astrazeneca Ab | Therapeutic quinazoline compounds |
| JP4820518B2 (ja) * | 2000-01-24 | 2011-11-24 | アストラゼネカ アクチボラグ | モルホリノ置換化合物治療薬 |
| GB0028702D0 (en) | 2000-11-24 | 2001-01-10 | Novartis Ag | Organic compounds |
| US20030221931A1 (en) | 2002-02-28 | 2003-12-04 | Steve Marsh | Sliding device |
| WO2003080585A1 (en) * | 2002-03-26 | 2003-10-02 | Banyu Pharmaceutical Co., Ltd. | Novel aminobenzamide derivative |
| WO2005108431A1 (en) | 2004-05-04 | 2005-11-17 | University Of Kentucky Research Foundation | Methods and compositions for the treatment of ocular neovascularization |
| WO2007052173A2 (en) | 2005-02-23 | 2007-05-10 | Endocube S.A.S. | Activity of thap-family chemokine-binding domains |
| CA2639115A1 (en) | 2006-02-17 | 2007-08-23 | Rappaport Family Institute For Research In The Medical Sciences | Molecules and methods of using same for treating ccr5/ccr5 ligands associated diseases |
| CA2681481A1 (en) | 2007-03-16 | 2008-09-25 | Mount Sinai School Of Medicine | Induction and/or maintenance of tumor dormancy by disruption of urokinase plasminogen activator receptor-integrin interaction |
| CN101202347A (zh) | 2007-11-22 | 2008-06-18 | 山东神工海特电子科技有限公司 | 具有金属骨架正极的1.5v锂二硫化铁扣式电池 |
| MX353776B (es) | 2009-06-12 | 2018-01-29 | Abivax | Compuestos utiles para tratar cancer. |
| KR20120046163A (ko) | 2009-06-15 | 2012-05-09 | 바이오카인 테라퓨틱스 리미티드 | 자가면역, 염증 및 암의 과정을 저해할 수 있는 신규한 케모카인 결합 폴리펩타이드류 |
| CN103517896B (zh) * | 2011-03-07 | 2016-09-21 | 葛兰素史密斯克莱有限责任公司 | 喹啉酮衍生物 |
| US20170226157A1 (en) | 2014-12-09 | 2017-08-10 | Biokine Therapeutics Ltd. | Compositions and methods for the treatment of ocular diseases |
| GB201519340D0 (en) | 2015-11-02 | 2015-12-16 | Cambridge Entpr Ltd | Methods of T-lymphocyte expansion |
| CA3008107C (en) | 2015-12-17 | 2023-06-27 | Biokine Therapeutics Ltd. | 8-phenoxy-quinoline derivatives for inhibiting chemokine activity and/or cancer cells growth |
| WO2017103931A1 (en) | 2015-12-17 | 2017-06-22 | Biokine Therapeutics Ltd. | Small molecules against cancer |
| EP3759074B1 (en) | 2019-05-15 | 2025-01-01 | AlonBio Ltd. | Small molecules for treating cancer, inhibiting chemokine activity and/or inducing cell death |
-
2016
- 2016-12-15 CA CA3008107A patent/CA3008107C/en active Active
- 2016-12-15 JP JP2018531613A patent/JP6941611B2/ja active Active
- 2016-12-15 EP EP16875067.7A patent/EP3390364B1/en active Active
- 2016-12-15 ES ES16875067T patent/ES2818531T3/es active Active
- 2016-12-15 AU AU2016371466A patent/AU2016371466B2/en active Active
- 2016-12-15 US US16/063,279 patent/US11129824B2/en active Active
- 2016-12-15 EP EP20185763.8A patent/EP3741432B1/en active Active
- 2016-12-15 MX MX2018007361A patent/MX382300B/es unknown
- 2016-12-15 DK DK16875067.7T patent/DK3390364T3/da active
- 2016-12-15 KR KR1020187020455A patent/KR102828755B1/ko active Active
- 2016-12-15 ES ES20185763T patent/ES2951385T3/es active Active
- 2016-12-15 MX MX2020011500A patent/MX2020011500A/es unknown
- 2016-12-15 CN CN201680081132.9A patent/CN108699000B/zh active Active
- 2016-12-15 WO PCT/IL2016/051347 patent/WO2017103932A1/en not_active Ceased
-
2018
- 2018-06-17 IL IL260081A patent/IL260081B/en unknown
-
2020
- 2020-07-07 AU AU2020204524A patent/AU2020204524B9/en active Active
-
2021
- 2021-09-27 US US17/485,581 patent/US12233057B2/en active Active
-
2025
- 2025-01-16 US US19/023,642 patent/US20250161291A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2021001228A1 (es) | Compuestos y composiciones para el tratamiento de afecciones asociadas con la actividad de nlrp | |
| NI201900019A (es) | Inhibidores de procesos metabólicos celulares | |
| CO2020002961A2 (es) | Activadores de piruvato quinasas para usar en el tratamiento de trastornos en la sangre | |
| CU20150119A7 (es) | 3-pirimidin-4-il-oxazolidin-2-onas como inhibidores de idh mutante | |
| UY35596A (es) | Compuestos para la modulación de quinasas, y sus indicaciones | |
| CL2017002786A1 (es) | Referencia cruzada a solicitudes relacionadas | |
| MX2017002206A (es) | Compuestos de indazol como inhibidores de cinasa fgfr, preparacion y uso de los mismos. | |
| JOP20190194A1 (ar) | مركبات نيوكليوتيدات ثنائية حلقية لعلاج السرطان | |
| CU24411B1 (es) | Compuesto derivado de benzamida sustituida con 1,3-tiazol-2-ilo útil para el tratamiento de trastornos neurogénicos | |
| MX2015015738A (es) | Derivados del bipirazol como inhibidores de janus cinasa (jak). | |
| CO2017001884A2 (es) | Polimorfos de selinexor | |
| MX2017006283A (es) | Peptidos macrociclicos utiles como inmunomoduladores. | |
| UY34750A (es) | ?compuestos para el tratamiento del hiv, composiciones,métodos de preparación, intermediarios y métodos terapéuticos?. | |
| MX371312B (es) | Pirazolil-ureas como inhibidores de quinasas. | |
| ECSP18012103A (es) | Inhibidores del receptor del factor estimulador de colonias 1 (csf-1r) | |
| MX2017006302A (es) | Derivados de adenina que son utiles en el tratamiento de enfermedades alergicas u otras afecciones inflamatorias. | |
| JO3512B1 (ar) | مشتقات كينوكسالين مفيدة كمعدلات لإنزيم fgfr كيناز | |
| SV2017005405A (es) | Compuestos y composiciones como inhibidores de quinasa raf | |
| MX2016001587A (es) | Inhibidores de kdm1a para el tratamiento de enfermedades. | |
| PE20151023A1 (es) | Triazolopirazinas | |
| EA201400990A1 (ru) | Ингибиторы диацилглицеринацилтрансферазы 2 | |
| UY36747A (es) | Compuestos de aminopiridina sustituida con heteroarilo como inhibidores de quinasa y modulantes de irak-4 y composiciones farmacéuticas que los contienen | |
| UY36749A (es) | Compuestos de aminopiridina sustituida con heteroarilo como inhibidores de quinasa y moduladores de irak-4, y composiciones farmacéuticas que los contienen | |
| CO2017001528A2 (es) | Compuestos novedosos de pirimidina sustituidos | |
| CO2017001506A2 (es) | Compuestos novedosos de pirimidina sustituidos |